相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
K Wyatt et al.
HEALTH TECHNOLOGY ASSESSMENT (2014)
Long-Term Survival and Late Deaths after Hematopoietic Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism
Mary Eapen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation
Chunfu Li et al.
BLOOD (2012)
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan
Maria Ester Bernardo et al.
BLOOD (2012)
Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients
T-H Jaing et al.
BONE MARROW TRANSPLANTATION (2012)
Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years
Carla E. M. Hollak et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Long-term follow up after allogeneic stem cell transplantation in patients with severe aplastic anemia after cyclophosphamide plus antithymocyte globulin conditioning
Johanna Konopacki et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Cardiovascular Complications in Long-Term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation
Alicia Rovo et al.
SEMINARS IN HEMATOLOGY (2012)
Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now
Matthew M. Hsieh et al.
BLOOD (2011)
Type 2 Gaucher disease: Phenotypic variation and genotypic heterogeneity
N. Gupta et al.
BLOOD CELLS MOLECULES AND DISEASES (2011)
Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease
D. Elstein et al.
BLOOD CELLS MOLECULES AND DISEASES (2011)
A French experience of type 3 Gaucher disease: Phenotypic diversity and neurological outcome of 10 patients
Ichraf Kraoua et al.
BRAIN & DEVELOPMENT (2011)
Therapeutic approaches to bone pathology in Gaucher disease: Past, present and future
Ozlem Goker-Alpan
MOLECULAR GENETICS AND METABOLISM (2011)
Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience
Ari Zimran et al.
BLOOD (2010)
The risk of Parkinson's disease in type 1 Gaucher disease
Gilberto Bultron et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2010)
Mutations for Gaucher Disease Confer High Susceptibility to Parkinson Disease
Jun Mitsui et al.
ARCHIVES OF NEUROLOGY (2009)
Goal-oriented therapy with miglustat in Gaucher disease
Gregory M. Pastores et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose-response relationships
Carla E. M. Hollak et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project
Pilar Giraldo et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Drug Shortages and Public Health
Robert Steinbrook
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell Disease.
Matthew M. Hsieh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
E. Sidransky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study
K. B. Sims et al.
CLINICAL GENETICS (2008)
Late cardiovascular events after allogeneic hematopoietic stem cell transplantation:: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation
Andre Tichelli et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Eight-Year Clinical Outcomes of Long-Term Enzyme Replacement Therapy for 884 Children With Gaucher Disease Type 1
Hans Andersson et al.
PEDIATRICS (2008)
Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation
Andre Tichelli et al.
BLOOD (2007)
High levels of human chitotriosidase hinder the formation of peritrophic membrane in anopheline vectors
M. Di Luca et al.
PARASITOLOGY RESEARCH (2007)
Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease
Richard J. Wenstrup et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Chitotriosidase: the yin and yang
L. Malaguarnera
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
Allogeneic hematopoietic stem cell transplantation for inherited disorders:: Experience in a single center
O Ringdén et al.
TRANSPLANTATION (2006)
Dendritic cells in patients with type I Gaucher disease are decreased in number but functionally normal
I Micheva et al.
BLOOD CELLS MOLECULES AND DISEASES (2006)
Quality of life related to type 1 Gaucher disease:: Spanish experience
P Giraldo et al.
QUALITY OF LIFE RESEARCH (2005)
New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years
P Sodani et al.
BLOOD (2004)
Therapeutic goals in the treatment of Gaucher disease
GM Pastores et al.
SEMINARS IN HEMATOLOGY (2004)
Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease
M Merad et al.
NATURE MEDICINE (2004)
Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines
C Peters et al.
BONE MARROW TRANSPLANTATION (2003)
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher Registry
NJ Weinreb et al.
AMERICAN JOURNAL OF MEDICINE (2002)
Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes
G La Nasa et al.
BLOOD (2002)
分享论文
